Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial

Psychiatry Research

Volumn 219, Issue 3, 2014, Pages 431-435

  Ghanizadeh, Ahmad ^a,b   Rezaee, Zahra ^a   Dehbozorgi, Sara ^a   Berk, Michael ^c,d   Akhondzadeh, Shahin ^e  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Inflammation; Lovastatin; Oxidative stress; Risperidone; Schizophrenia; Statins

Indexed keywords

MEVINOLIN; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INCREASED APPETITE; LIBIDO DISORDER; MOTOR DYSFUNCTION; MOVEMENT SLOWNESS; MUSCLE RIGIDITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; DOSE RESPONSE; DRUG COMBINATION; FEMALE; MALE; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOVASTATIN; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84907598111     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.06.039     Document Type: Article

References (39)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 2007, 90:179-185.
2. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophrenia Research 1999, 37:97-106.
3. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Judd F., Katz F., Katz P., Ording-Jespersen S., Little J., Conus P., Cuenod M., Do K.Q., Bush A.I. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biological Psychiatry 2008, 64:361-368.
4. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Bush A.I. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biological Psychiatry 2008, 64:468-475.
5. Berk M., Dean O., Drexhage H., McNeil J.J., Moylan S., O'Neil A., Davey C.G., Sanna L., Maes M. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Medicine 2013, 11:74.
6. Castro A.A., Wiemes B.P., Matheus F.C., Lapa F.R., Viola G.G., Santos A.R., Tasca C.I., Prediger R.D. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease. Brain Research 2013, 1513:103-116.
7. Chang S.H., Chiang S.Y., Chiu C.C., Tsai C.C., Tsai H.H., Huang C.Y., Hsu T.C., Tzang B.S. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Research 2011, 30(187):341-346.
8. Chen C.C., Tsai T.H., Huang Z.R., Fang J.Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. European Journal of Pharmaceutics and Biopharmaceutics 2010, 74:474-482.
9. Chen S.F., Hung T.H., Chen C.C., Lin K.H., Huang Y.N., Tsai H.C., Wang J.Y. Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. Life Sciences 2007, 81:288-298.
10. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity 2007, 21:153-160.
11. De Hert M., Kalnicka D., van Winkel R., Wampers M., Hanssens L., Van Eyck D., Scheen A., Peuskens J. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 2006, 67:1889-1896.
12. Donev, R., Thome, J., 2010 Inflammation: good or bad for ADHD? Attention Deficit Hyperactivity Disorder 2, 257-266.
13. Expert Panel on Detection, E., Treatment of High Blood Cholesterol in Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
14. Fond G., Hamdani N., Kapczinski F., Boukouaci W., Drancourt N., Dargel A., Oliveira J., Le Guen E., Marlinge E., Tamouza R., Leboyer M. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatrica Scandinavica 2014, 129:163-179.
15. Ghanizadeh A., Hedayati A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depression and Anxiety 2013, 30:1084-1088.
16. Ghanizadeh, A., OmraniSigaroodi, M., Javadpour, A., DabbaghManesh, M.H., Shafiee, S., 2014. Lovastatin as an adjuvant to lithium for treating manic phase of bipolar disorder: a 4-week, randomized, double-blind, placebo-controlled clinical trial. Depression Research and Treatment. (in Press).
17. Gouveia, T.L., Scorza, F.A., Silva, M.J., Bandeira Tde, A., Perosa, S.R., Arganaraz, G.A., Silva Mde, P., Araujo, T.R., Frangiotti, M.I., Amado, D., Cavalheiro, E.A., Silva, J.A., Jr., Naffah-Mazzacoratti Mda, G., 2014 Lovastatin decreases the synthesis of inflammatory mediators in the hippocampus and blocks the hyperthermia of rats submitted to long-lasting status epilepticus. Epilepsy & Behavior 20, 1-5.
18. Hamazaki K., Hamazaki T., Inadera H. Abnormalities in the fatty acid composition of the postmortem entorhinal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder. Psychiatry Research 2013, 210:346-350.
19. Hernandez-Romero M.C., Arguelles S., Villaran R.F., de Pablos R.M., Delgado-Cortes M.J., Santiago M., Herrera A.J., Cano J., Machado A. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. Journal of Neurochemistry 2008, 105:445-459.
20. Hoen W.P., Lijmer J.G., Duran M., Wanders R.J., van Beveren N.J., de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Research 2013, 207:1-12.
21. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
22. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
23. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 2010, 71:520-527.
24. Landry P., Dimitri E., Tessier S., Legare N. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Journal of Clinical Psychopharmacology 2008, 28:348-349.
25. Mansi I., Frei C.R., Pugh M.J., Mortensen E.M. Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy 2013, 33:615-626.
26. Mascitelli L., Pezzetta F., Goldstein M.R. Is statin use safe in individuals with psychotic disorders?. Journal of Clinical Psychiatry 2008, 69:1499.
27. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., Yao J., Peters J.L. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. American Journal of Psychiatry 1995, 152:1291-1297.
28. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011, 70:663-671.
29. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., Ulmschneider M., Engel R.R., Moller H.J., Schwarz M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 2002, 159:1029-1034.
30. O'Neil A., Sanna L., Redlich C., Sanderson K., Jacka F., Williams L.J., Pasco J.A., Berk M. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Medicine 2012, 10:154.
31. Parsaik A.K., Singh B., Hassan Murad M., Singh K., Mascarenhas S.S., Williams M.D., Lapid M.I., Richardson J.W., West C.P., Rummans T.A. Statins use and risk of depression: a systematic review and meta-analysis. Journal of Affective Disorders 2014, 160:62-67.
32. Singh B., Bera N.K., Nayak C.R., Chaudhuri T.K. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009, 47:1-5.
33. Smith S.E., Li J., Garbett K., Mirnics K., Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. Journal of Neuroscience 2007, 27:10695-10702.
34. Soderlund J., Schroder J., Nordin C., Samuelsson M., Walther-Jallow L., Karlsson H., Erhardt S., Engberg G. Activation of brain interleukin-1beta in schizophrenia. Molecular Psychiatry 2009, 14:1069-1071.
35. Song X.Q., Lv L.X., Li W.Q., Hao Y.H., Zhao J.P. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biological Psychiatry 2009, 65:481-488.
36. Tourjman V., Kouassi E., Koue M.E., Rocchetti M., Fortin-Fournier S., Fusar-Poli P., Potvin S. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophrenia Research 2013, 151:43-47.
37. Vincenzi B., Borba C.P., Gray D.A., Copeland P.M., Wang X., Fan X., Aragam G.G., Henderson D.C. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics. Annals of Clinical Psychiatry 2013, 25:141-148.
38. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. Journal of Clinical Psychiatry 2002, 63:856-865.
39. Zhang Y.Y., Fan Y.C., Wang M., Wang D., Li X.H. Atorvastatin attenuates the production of IL-1beta, IL-6, and TNF-alpha in the hippocampus of an amyloid beta1-42-induced rat model of Alzheimer's disease. Clinical Interventions in Aging 2013, 8:103-110.